This trial aims to determine if receiving their own stem cells immediately after a stroke can be of benefit to patients. The trial is being conducted at the Sungkyunkwan University School of Medicine and Samsung Medical Centre in Seoul in conjunction with Pharmicell Ltd. Participants will be randomly divided into either a control group which will receive standard treatment only, and an experimental group that will receive their own stem cells obtained from bone marrow and expanded in the laboratory. Participants will be monitored for complications and changes in clinical condition. The trial is scheduled to run from November 2012 to February 2016 and proposes to recruit 60 patients in the acute phase of an ischaemic stroke.